Navigation Links
Dry beans inhibit development of mammary cancer
Date:2/4/2009

Madison, WI, February 2, 2009 - As the world seeks new ways to prevent and treat chronic diseases such as diabetes, heart disease and cancer, more research continues to be conducted on the benefits of certain foods in reducing people's risk of contracting these ailments. Legumes in particular are often cited as being high in antioxidants, which have the property of being able to fight off free radical cells within the body, reducing the risk of cancer and other chronic diseases. A recent study further investigated these connections, as researchers focused on the benefits of one type of legume, dry beans, in reducing the risk of mammary cancer.

To address whether dry bean consumption is associated with a reduction in mammary cancer, scientists at Colorado State University studied the anticancer activity of six market classes of bean including; small red, great northern, navy, black, dark red and white kidney bean in the diet of laboratory animals. They also evaluated whether the level of antioxidants or seed coat pigments in the bean were related to mammary cancer. The study was funded by a grant from the Beans for Health Alliance, and the Colorado Agricultural Experiment Station with assistance from Archer Daniels Midland Co. and Bush Brothers Inc. Results from the study were published in the January-February 2009 issue of the journal Crop Science.

Cooked dry bean powder from the six market classes and a control group without beans in the diet were fed to laboratory rats in a standard preclinical model for breast cancer. The dry bean powders were also evaluated for antioxidant capacity, phenolic and flavonoid content; all factors thought to be associated with anticancer activity. Chemical analysis of the beans revealed that total phenolic and flavonoid content varied widely among market classes and the differences were strongly associated with seed coat color; where colored beans had ten times or greater phenolic and flavonoid content compared to white beans. Antioxidant capacity of the beans also varied widely among dry bean market classes and were highly related to seed coat color, where colored beans had approximately two to three times greater antioxidant capacity than white beans.

Dry bean consumption from every market class reduced cancer incidence (number of animals with one tumor) and tumor number per animal compared to the control group. Cancer incidence was reduced from 95% in the control group to 67% in animals fed beans. The average number of malignant tumors was also reduced from 3.2 in the control group to 1.4 tumors per animal in the group fed bean. No associations were observed between phenolic content, flavonoid content and antioxidant capacity with cancer among the bean market classes. These results clearly suggest that the anticancer activity in dry bean is not associated with seed color or antioxidant capacity.

Research is ongoing at Colorado State University to investigate the mechanisms and molecules that contribute to the anticancer properties of dry bean. Clinical trials are also underway to determine if bean in the diet of humans are associated with biomarkers for cancer incidence.


'/>"/>

Contact: Sara Uttech
suttech@crops.org
608-268-4948
Crop Science Society of America
Source:Eurekalert

Related medicine news :

1. Black Caribbeans do better in America than in England
2. Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
3. Coffee Beans May Be Newest Stress-Buster
4. Potent peptides inhibit HIV entry into cells
5. New All-Natural Dietary Supplement Made from Muscadine Grape Skins Helps Inhibit Growth of Certain Cancers
6. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
7. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
10. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
11. Silencing small but mighty cancer inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: